✦ LIBER ✦

Treatment–subgroup interaction: An example from a published, phase II clinical trial

✍ Scribed by Carolyn E. Behrendt; Edmund A. Gehan

Book ID: 116350799
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 117 KB
Volume: 30
Category: Article
ISSN: 1551-7144
DOI: 10.1016/j.cct.2009.02.002

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Simulation as a design tool for phase I/

Simulation as a design tool for phase I/II clinical trials: An example from bone marrow transplantation

✍ Ted A. Gooley; Paul J. Martin; Lloyd D. Fisher; Mary Pettinger 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 892 KB

CELECOXIB FOR THE TREATMENT OF NON MUSCL

CELECOXIB FOR THE TREATMENT OF NON MUSCLE INVASIVE BLADDER CANCER. RESULTS FROM THE FIRST PHASE II CLINICAL TRIAL

✍ V. Pagliarulo; I. Martines; S. Telari; P. Ancona; P. Trerotoli; G. Albo; A. Pagl 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 86 KB

90Yttrium-Ibritumomab-Tiuxetan as First-

90Yttrium-Ibritumomab-Tiuxetan as First-Line Treatment for Follicular Lymphoma: 30 Months of Follow-Up Data From an International Multicenter Phase II Clinical Trial

✍ Scholz, C. W.; Pinto, A.; Linkesch, W.; Linden, O.; Viardot, A.; Keller, U.; Hes 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 133 KB

Raloxifene, an oestrogen-receptor-β-targ

Raloxifene, an oestrogen-receptor-β-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial

✍ RONALD L. SHAZER; ANJALI JAIN; ANNA V. GALKIN; NADYA CINMAN; KOO N. NGUYEN; RONA 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 595 KB

An open-label Phase I/II clinical trial

An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay–Sachs or Sandhoff variants)

✍ Joe T.R. Clarke; Don J. Mahuran; Swati Sathe; Edwin H. Kolodny; Brigitte A. Riga 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 340 KB

An Analysis of Safety Data from Five Pha

An Analysis of Safety Data from Five Phase III Clinical Trials on the Use of Botulinum Neurotoxin Type A-ABO for the Treatment of Glabellar Lines

✍ Mark Rubin; Jeffrey Dover; Corey Maas; Mark Nestor 📂 Article 📅 2009 🏛 Sage Publications 🌐 English ⚖ 172 KB